- Rating
- 1
- Confidence
- 2
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 1
Read review
Paper summary
The paper studies and validates FaceAge in patients with oligometastatic cancer for prognosis. The paper collects/utilizes a private dataset containing 177 patients with 1 to 5 distant metastases from 2014 to 2023. Unlike previous studies, the authors found that FaceAge did not outperform chronological age in predicting overall survival.
Critical strengths
- The study addresses a real-world clinical problem of predicting survival in a specific type of cancer.
- The authors compare FaceAge as a biomarker of survival with other biomarkers comprehensively and investigate sub-population performance (e.g. race).
Critical weaknesses
- The study involves only 177 patients from only from 1 site, as far as I understand, and has a highly imbalanced patient background (145 white, 20 black, 12 other race). This dataset size is very small compared to previous similar studies, which makes the paper's claim less convincing. For reference: [1] (6,196 patients), [2] (24,556 patients), [3] (2,276 patients), [4] (670 patients).
- While the authors provide p-values for statistical significance, there are inconsistencies in their interpretations. In Line 165, the authors say "mean FaceAge 2.0 estimate for Black patients was 1.4 years older than calendar age (p=0.62)", which I believe the interpretation is inaccurate, as the null hypothesis cannot be rejected because of a high p-value. In other places, such as in Line 198, the authors acknowledge a statistically insignificant association between FaceAge and post-radiation systemic therapy intensity based on p-values.
- The authors include their main figure and tables after the References, which should be considered an Appendix. This makes reading uncomfortable, especially when looking at the main findings provided in the figure and tables.
References:
- "FaceAge, a deep learning system to estimate biological age from face photographs to improve prognostication: a model development and validation study", The Lancet Digital Health, 2025.
- "FaceAge as a biomarker for prognosis and treatment stratification in a large-scale oncology cohort", J Natl Cancer Inst., 2026.
- "Face aging rate quantifies change in biological age to predict cancer outcomes", Nature Communications, 2026.
- "Multimodal Assessment of Biological Age Following Radiation Therapy Among Patients With Early-Stage NSCLC", JAMA Netw Open, 2026.
Questions for authors
- Lines 119-120. Do the authors perform sub-population survival analysis for patients with recorded dates of death and dates of last follow-up?
- Is it possible to estimate biological age more reliably than by looking at patients’ photographs? If yes, do the authors try to verify FaceAge estimation with a more reliable method?